Experience with crystalline niacin as the preferred drug for dyslipidemia in a specialty clinic

Pharmacotherapy

Volumn 17, Issue 6, 1997, Pages 1296-1299

  Rindone, Joseph P ^a   Arriola, O Greg ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINIC ACID;

ADULT; AGED; ARTICLE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; FLUSHING; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM PERMISSIBLE DOSE; SKIN MANIFESTATION; SKIN TINGLING; TREATMENT FAILURE;

EID: 0030662291     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1875-9114.1997.tb03095.x     Document Type: Article

References (21)

1. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-98.
2. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-55.
3. Dunn RT, Ford MA, Rindone JP, Kwiecinski FA. Low-dose aspirin and ibuprofen reduce the cutaneous reactions following niacin administration. Am J Ther 1995;2:478-80.
4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II). JAMA 1993;269:3015-23.
5. Friedewald WT, Levy RI, Tredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without the use of the preparative centrifuge. Clin Chem 1972;18:499-502.
6. Martin-Jadraque R, Tato F, Mostaza JM, et al. Effectiveness of low-dose crystalline nicotinic acid in men with low highdensity lipoprotein cholesterol levels. Arch Intern Med 1996:156:1081-8.
7. Illingworth DR, Stein EA, Mitchell YB, et al. Comparative effects of lovastatin and niacin in primary hypercholesterolemia. Arch Intern Med 1994;154:1586-95.
8. The Coronary Drug Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360-81.
9. McKenny JM, Proctor JD, Harris S, Chinchili VM. Comparison of the efficacy and toxic effects of sustained-vs immediate-release niacin in hypercholesterolemic patients. JAMA 1994;271:672-7.
10. Schectman G, Hiatt J, Hartz A. Evaluation of the effectiveness of lipid-lowering therapy (bile acid sequestrants, niacin, psyllium, and lovastatin) for treating hypercholesterolemic veterans. Am J Cardiol 1993;71:759-65.
11. Knopp RH, Ginsberg J, Albers JJ, et al. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects. Clue to mechanism of action of niacin. Metabolism 1985;34:642-50.
12. Andrade SE, Walker AM, Gottlieb LK, et al. Discontinuation of antihyperlipidemic drugs-do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 1995;332: 1125-31.
13. Gibbons LW, Gonzalez V, Gordon N, Grundy S. The prevalence of side effects with regular and sustained-release nicotinic acid. Am J Med 1996;99:378-85.
14. McEvoy GK, Litvak K, Welsh OH, eds. Drug information 96. Niacin monograph. Bethesda, MD: American Society of HealthSystem Pharmacists, 1996:1260-63.
15. Bennett DR. Drug evaluations. Treatment of disorders of cholesterol and lipoprotein metabolism. Chicago: American Medical Association, 1994:7:1-7:46.
16. Rader JI, Calvert RJ, Hathcock JN. Hepatic toxicity of unmodified and time-release preparations of niacin. Am J Med 1992; 92:77-81.
17. Probstfield JL. Nicotinic acid as a lipoprotein-altering agent. Arch Intern Med 1996;154:1557-9.
18. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-98.
19. Kinosian B, Click H, Garland G. Cholesterol and coronary heart disease: predicting risks by levels and ratios. Ann Intern Med 1994;121:641-7.
20. Brown SL, Sobel BE, Fujii S. Attenuation of the synthesis of plasminogen activator inhibitor type 1 by niacin. A potential link between lipid lowering and fibrinolysis. Circulation 1995;92:767-72.
21. Chait A, Brazg RL, Tribble DL, Kraus RM. Susceptibility of small dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, type B. Am J Med 1993;94:350-6.